Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98.6M
-
Number of holders
-
182
-
Total 13F shares, excl. options
-
76.2M
-
Shares change
-
+4.93M
-
Total reported value, excl. options
-
$959M
-
Value change
-
+$63.8M
-
Put/Call ratio
-
2.15
-
Number of buys
-
96
-
Number of sells
-
-74
-
Price
-
$12.58
Significant Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q1 2025
215 filings reported holding SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q1 2025.
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) has 182 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 76.2M shares
of 98.6M outstanding shares and own 77.33% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (10.9M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (10.5M shares), ORBIMED ADVISORS LLC (8.29M shares), BlackRock, Inc. (4.3M shares), SR One Capital Management, LP (4.01M shares), ALLIANCEBERNSTEIN L.P. (3.92M shares), VANGUARD GROUP INC (3.49M shares), STATE STREET CORP (2.03M shares), FRANKLIN RESOURCES INC (1.86M shares), and Cormorant Asset Management, LP (1.6M shares).
This table shows the top 182 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.